[Form 4] SEMPRA Insider Trading Activity
Rhea-AI Filing Summary
Kevin C. Sagara, a director of Sempra (SRE), reported the sale of 14,433 shares of the company's common stock on 09/29/2025 at a price of $89.50 per share under a previously established Rule 10b5-1 trading plan dated March 19, 2025. The Form 4 shows Mr. Sagara retains a direct beneficial ownership stake following the reported transaction and also holds an indirect interest of 2,404.47 shares through a 401(k) savings plan as of 09/26/2025. The filing was signed by an attorney-in-fact on Mr. Sagara's behalf and includes a Power of Attorney exhibit.
Positive
- Sale executed under a Rule 10b5-1(c) trading plan, reducing concerns about opportunistic insider timing
- Filing includes Exhibit 24 (Power of Attorney), indicating procedural formalities were followed
- Disclosure of indirect holdings in a 401(k) plan (2,404.47 shares) shows continued ownership alignment
Negative
- Director disposed of 14,433 shares at $89.50, a potentially material sale depending on the director's total holdings
- Post-transaction direct beneficial ownership figure is reported in a nonstandard numeric format in the filing, which could cause ambiguity for some readers
Insights
TL;DR: Director sold a meaningful block of SRE shares under a pre-set 10b5-1 plan; transaction is routine but increases share supply from insider.
The reported disposal of 14,433 shares at $89.50 under a March 19, 2025 Rule 10b5-1 plan indicates the sale was pre-authorized and not the result of contemporaneous, discretionary trading. For investors this reduces concerns about opportunistic timing by the director, though the size of the sale is notable relative to a typical director holding. The filing also discloses indirect holdings of 2,404.47 shares in a 401(k) plan, which provides some ongoing alignment with shareholder interests. No derivative transactions or additional material events are reported.
TL;DR: Use of a Rule 10b5-1 plan and POA signature suggests governance controls were followed for the insider sale.
The Form 4 explicitly states the sale complied with a written instruction and a 10b5-1(c) plan, which is the accepted governance mechanism for scheduled insider trades and helps mitigate insider trading concerns. The signature by an attorney-in-fact and inclusion of Exhibit 24 (Power of Attorney) are consistent with procedural requirements for filings. There are no disclosures of accelerated option exercises, stock-based awards, or other governance actions in this filing.